{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:52:18Z","timestamp":1777909938804,"version":"3.51.4"},"reference-count":64,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:p>The use of contact lenses as ocular drug delivery systems has been considered intuitive for decades. However, at this time, there are no approved products using such systems. In this article, we review the challenges with current therapies, pharmacokinetics, and pharmacodynamics of different drug classes and the patient population. In addition, we note the relative lack of clinical studies, and list potential products in active development at this time. In particular, we address the alignment of time course of the therapeutic need, the pharmacokinetics of the molecule, and the delivery characteristics of the systems (e.g., pulsatile vs. zero-order). We also discuss the needs of various populations including the elderly (who may have motor and cognitive issues as well as presbyopia) and the young. While a contact lens delivery system may also provide refractive correction, to date, most of the studies have used noncorrective (plano) lenses. We also considered nanotechnology-based carrier systems. We generalize the development of contact lens delivery systems to all ocular delivery systems in which there are relatively few product approvals and long development times.<\/jats:p>","DOI":"10.1089\/jop.2020.0024","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T22:23:12Z","timestamp":1590531792000},"page":"595-601","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Ocular Drug Delivery Systems Using Contact Lenses"],"prefix":"10.1177","volume":"36","author":[{"given":"Gary D.","family":"Novack","sequence":"first","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Sciences, University of California, Davis, California, USA."},{"name":"PharmaLogic Development, Inc., San Rafael, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Barnett","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology &amp; Visual Sciences, University of California, Davis, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"264","article-title":"Determination of tear volume and tear flow","volume":"5","author":"Mishima S.","year":"1966","unstructured":"Mishima S., , Gasset A., , Klyce S.D., , and Baum J.L. Determination of tear volume and tear flow. Invest. Ophthalmol. Vis. Sci. 5:264\u2013276, 1966.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600761005"},{"key":"e_1_3_3_4_2","first-page":"509","article-title":"Possibility of the application of ophthalmic drugs with the use of gel contact lenses","volume":"21","author":"Sedlacek J.","year":"1965","unstructured":"Sedlacek J. Possibility of the application of ophthalmic drugs with the use of gel contact lenses. Cesk. Oftalmol. 21:509\u2013512, 1965.","journal-title":"Cesk. Oftalmol"},{"key":"e_1_3_3_5_2","first-page":"361","article-title":"The medical uses of soft contact lenses","volume":"75","author":"Kaufman H.E.","year":"1971","unstructured":"Kaufman H.E., , Uotila M.H., , Gasset A.R., , Wood T.O., , and Ellison E.D. The medical uses of soft contact lenses. Trans. Am. Acad. Ophthalmol. Otolaryngol. 75:361\u2013373, 1971.","journal-title":"Trans. Am. Acad. Ophthalmol. Otolaryngol"},{"key":"e_1_3_3_6_2","unstructured":"Schultz C.L. Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease 2007. (accessed January30 2017)."},{"key":"e_1_3_3_7_2","unstructured":"Schultz C.L. and Mint J.M. Drug delivery system for antiglaucomatous medication 2002. (accessed June25 2002)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.297"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.01.023"},{"key":"e_1_3_3_10_2","first-page":"427","article-title":"A., Gerber, A., et al","volume":"98","author":"Kim N.J.","year":"2014","unstructured":"Kim N.J., Harris. A., Gerber, A., et al. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Br. J. Ophthalmol. 98:427\u2013431, 2014.","journal-title":"Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Br. J. Ophthalmol"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000209665"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/admt.201900728"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.05.020"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001911"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050635"},{"key":"e_1_3_3_16_2","first-page":"4","article-title":"State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug","volume":"4","author":"Babizhayev M.A.","year":"2009","unstructured":"Babizhayev M.A., , and Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr. Clin. Pharmacol. 4:4\u201337, 2009.","journal-title":"Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr. Clin. Pharmacol"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.b.30613"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00919405"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-19960101-05"},{"key":"e_1_3_3_20_2","first-page":"866","article-title":"Evaluation of \u201cbacteriostatic\u201d","volume":"61","author":"Chalkley T.","year":"1966","unstructured":"Chalkley T., , Sarnat L., , and Shoch D. Evaluation of \u201cbacteriostatic\u201d. contact lenses. A double-blind study. Am. J. Ophthalmol. 61:866\u2013869, 1966.","journal-title":"contact lenses. A double-blind study. Am. J. Ophthalmol"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(84)90168-1"},{"key":"e_1_3_3_22_2","first-page":"1031","article-title":"Effect of pilocarpine ocular therapeutic systems on diurnal control of intraocular pressure","volume":"8","author":"Fraunfelder F.T.","year":"1976","unstructured":"Fraunfelder F.T., , Shell J.W., , and Herbst S.F. Effect of pilocarpine ocular therapeutic systems on diurnal control of intraocular pressure. Ann. Ophthalmol. 8:1031\u20131039, 1976.","journal-title":"Ann. Ophthalmol"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(86)90939-6"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)74225-4"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.06.012"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.96"},{"key":"e_1_3_3_27_2","first-page":"889","article-title":"Patient administration of eyedrops: observation","volume":"14","author":"Kass M.A.","year":"1982","unstructured":"Kass M.A., , Hodapp E., , Gordon M., , Kolker A.E., , and Goldberg I. Patient administration of eyedrops: observation. Part II. Ann. Ophthalmol. 14:889\u2013893, 1982.","journal-title":"Part II. Ann. Ophthalmol"},{"key":"e_1_3_3_28_2","first-page":"775","article-title":"Part I","volume":"14","author":"Kass M.A.","year":"1982","unstructured":"Kass M.A., , Hodapp E., , Gordon M., , Kolker A.E., , and Goldberg I. Part I. Patient administration of eyedrops: interview. Ann. Ophthalmol. 14:775\u2013779, 1982.","journal-title":"Patient administration of eyedrops: interview. Ann. Ophthalmol"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.040"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000574"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50226.x"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1995.11.319"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1994.10.17"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(13)80949-2"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2008.01.011"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9183-3"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2018.12.002"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0892-8967(01)00040-2"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1475-1313.2002.00066.x"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000248382.32143.86"},{"key":"e_1_3_3_41_2","unstructured":"Rumpakis J. New data on contact lens dropouts: an international perspective. Available at https:\/\/www.reviewofoptometry.com\/article\/new-data-on-contact-lens-dropouts-an-international-perspective. Accessed July27 2019."},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","unstructured":"Barnett M. and Johns L.K. Contemporary Scleral Lenses: Theory and Application. United Arab Emirates: Bentham Science Publishers; 2017; p. 214\u2013215.","DOI":"10.2174\/97816810856611170401"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801390"},{"key":"e_1_3_3_44_2","first-page":"27","volume-title":"Biopharmaceutics of Ocular Drug Delivery","author":"van Ooteghem M.M.M","year":"1993","unstructured":"van Ooteghem M.M.M. Formulation of ophthalmic solutions and suspensions. Problems and advantages. In: Edman P., ed. Biopharmaceutics of Ocular Drug Delivery. Boca Raton, Florida: CRC Press; 1993; p. 27\u201342."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.1.12"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70292-6"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.28"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.08.027"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.894084"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(11)70035-0"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/08820530902802013"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2018.11.008"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000045"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.2174\/9781681085661117040012"},{"key":"e_1_3_3_55_2","unstructured":"Vance K. Miller W. and Bermangson J. Measurement of tear flow in scleral contact lens wearers. The 94th American Academy of Optometry. New Orleans LA; 2015."},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2018.11.016"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.06.038"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119285"},{"key":"e_1_3_3_59_2","unstructured":"Doshi P. Medical devices including medicaments and methods of making and using same. US Patent 10 076 493 (accessed September18 2018)."},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000849"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2014.04.005"},{"key":"e_1_3_3_62_2","unstructured":"Byrne M.E. and Venkatesh S. Contact drug delivery system 2013. (accessed January13 2013)."},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-014-0196-9"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70131-3"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.634"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:02Z","timestamp":1777646642000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10,1]]}},"alternative-id":["10.1089\/jop.2020.0024"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0024","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}